Drug Safety, Part 3U.S. Government Printing Office, 1964 - Drugs |
Contents
| 821 | |
| 828 | |
| 834 | |
| 852 | |
| 865 | |
| 870 | |
| 879 | |
| 885 | |
| 1139 | |
| 1145 | |
| 1155 | |
| 1181 | |
| 1186 | |
| 1201 | |
| 1221 | |
| 1254 | |
| 893 | |
| 907 | |
| 924 | |
| 940 | |
| 957 | |
| 989 | |
| 1003 | |
| 1040 | |
| 1048 | |
| 1051 | |
| 1056 | |
| 1066 | |
| 1093 | |
| 1107 | |
| 1115 | |
| 1260 | |
| 1270 | |
| 1276 | |
| 1294 | |
| 1305 | |
| 1316 | |
| 1329 | |
| 1331 | |
| 1344 | |
| 1351 | |
| 1360 | |
| 1375 | |
| 1408 | |
| 1417 | |
Common terms and phrases
abnormalities action adverse reaction animal data animal studies animal tests antidepressant approved basis believe Bendroflumethiazide Bureau of Medicine Chairman chlorcyclizine Ciba clinical investigation clinical studies Commissioner cyclizine decision desmosterol discussed diuretic Division dosage dose Drug Administration drug application DWYER Dyazide evaluation experience Food and Drug FOUNTAIN GOLDBERG GRAY hoc committee hospitals human hydrochlorothiazide hypertension IND's indicated Investigational Drug Branch investigational new drug KELSEY Kline & French labeling LARRICK LATTA lesions matter meclizine meclizine and cyclizine Medical Director medical officer meeting memorandum Merck Naturetin opinion Palmisano Parnate patients percent pharmacologist physicians PISANI potassium potassium chloride pregnancy prescription present question RANKIN rats received recommendations reconvening record request responsibility SADUSK safety small bowel sponsor Squibb staff statement subcommittee submitted summary tablets teratogenic teratogenic effect tests thalidomide therapy thiazide tion toxicity tranylcypromine triamterene ulceration warning letter WEINSTEIN
Popular passages
Page 1258 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be, concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended,...
Page 1013 - Secretary when the application was approved, shows that such drug is not shown to be safe for use under the conditions of use upon the basis of which the application was approved...
Page 1104 - Register, to be in the public interest in connection with the performance of duties imposed on that agency by law.
Page 1307 - Secretary until after such application was approved, or tests by new methods, or tests by methods not deemed reasonably applicable when such application was approved...
Page 1317 - Administration with respect to such drug, there is lack of substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested...
Page 820 - The sponsor shall recall the unused supplies of the drug upon notification of the termination. (e) Where drugs were under clinical trial on man on or after August 10, 1962, the sponsor shall, within 30 days after these regulations become effective, submit a list of such investigational drugs, and within 120 days after such effective date shall submit to the Food and Drug Administration the completed "Notice of claimed investigational exemption for a new drug...
Page 888 - The sponsor shall promptly investigate and report to the Food and Drug Administration and to all investigators any findings associated with use of the drug that may suggest significant hazards, contraindications, sideeffects, and precautions pertinent to the safety of the drug.
Page 839 - ... program that is to be undertaken. 9. The names and a summary of the training and experience of each investigator and of the individual charged with monitoring the progress of the investigation and evaluating the evidence of safety and effectiveness of the drug as it is...
Page 839 - The scientific training and experience considered appropriate by the sponsor to qualify the Investigators as suitable experts to Investigate the safety of the drug, bearing In mind what is known about the pharmacological action of the drug and the phase of the investigational program that is to be undertaken.
Page 901 - The committee will stand in recess, subject to the call of the Chair. Thank you very much. [Whereupon, at 12:11 pm, Thursday, May 25, the subcommittee was recessed, to reconvene at the call of the Chair...